litlas
Log inCreate account

Mikhail Lichinitser

Active 2003–2019

28
Papers
20,663
Citations
27
h-index
28
i10-index

Citations

Citations per year for Mikhail Lichinitser1948: 1 citations1999: 1 citations2003: 1 citations2004: 9 citations2005: 23 citations2006: 67 citations2007: 102 citations2008: 113 citations2009: 161 citations2010: 213 citations2011: 227 citations2012: 213 citations2013: 255 citations2014: 206 citations2015: 202 citations2016: 214 citations2017: 173 citations2018: 172 citations2019: 626 citations2020: 647 citations2021: 554 citations2022: 350 citations2023: 253 citations2024: 365 citations2025: 153 citations2026: 3 citations1949–1998: no citations, so these years are not shown2000–2002: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,116 citing papers, 22.6% of this breakdownChina: 642 citing papers, 6.9% of this breakdownUnited Kingdom: 626 citing papers, 6.7% of this breakdownItaly: 592 citing papers, 6.3% of this breakdownGermany: 517 citing papers, 5.5% of this breakdownFrance: 416 citing papers, 4.4% of this breakdownAustralia: 350 citing papers, 3.7% of this breakdownSpain: 343 citing papers, 3.7% of this breakdownCanada: 330 citing papers, 3.5% of this breakdownJapan: 326 citing papers, 3.5% of this breakdownSwitzerland: 306 citing papers, 3.3% of this breakdownNetherlands: 281 citing papers, 3% of this breakdown
0%22.6%Other 26.9%

Institutions

Fields

  • Medicine69.7%
  • Biochemistry, Genetics and Molecular Biology24.8%
  • Immunology and Microbiology2.2%
  • Computer Science0.7%
  • Materials Science0.5%
  • Mathematics0.4%
  • Other1.7%

Topics

  • HER2/EGFR in Cancer Research8.2%
  • Breast Cancer Treatment Studies5.2%
  • Cancer Immunotherapy and Biomarkers4.9%
  • Colorectal Cancer Treatments and Studies4%
  • Cancer Treatment and Pharmacology3.4%
  • Advanced Breast Cancer Therapies3.3%
  • Other71%

Coauthors

All papers

Open in search
  1. Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma

    Authors: Alexander M.M. Eggermont, Christian U. Blank, Mario Mandalà, Georgina V. Long, Victoria Atkinson, Stéphane Dalle, Andrew Haydon, Mikhail Lichinitser, Adnan Khattak, Matteo S. Carlino, Shahneen Sandhu, James Larkin, Susana Puig, Paolo A. Ascierto, Piotr Rutkowski, Dirk Schadendorf, Rutger H.T. Koornstra, Leonel F. Hernandez‐Aya, Michele Maio, Alfonsus Johannes Maria van den Eertwegh, Jean-Jacques Grob, Ralf Gutzmer, Rahima Jamal, Paul Lorigan, Nageatte Ibrahim, Sandrine Marréaud, Alexander C. J. van Akkooi, Stefan Suciu, Caroline Robert - New England Journal of Medicine 2018 cited by 1,853

  2. Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer

    Authors: Martine Piccart, Marion Procter, Brian Leyland‐Jones, Aron Goldhirsch, Michael Untch, Ian Smith, Luca Gianni, José Baselga, Richard H. Bell, Christian Jackisch, David Cameron, Mitch Dowsett, Carlos H. Barrios, Günther Steger, Chiun‐Sheng Huang, Michael Andersson, Moshe Inbar, Mikhail Lichinitser, István Láng, Ulrike Nitz, Hiroji Iwata, Christoph Thomssen, Caroline Lohrisch, Thomas Suter, Josef Rüschoff, Tamás Sütö, Victoria Greatorex, Carol Ward, Carolyn Straehle, Eleanor McFadden, Mirko Dolci, Richard D. Gelber - New England Journal of Medicine 2005 cited by 5,098

  3. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort

    Authors: Luca Gianni, W. Eiermann, Semiglazov Vf, Alexey Manikhas, Aňa Lluch, S. Tjulandin, Milvia Zambetti, Federico Vázquez, Mikhail Byakhow, Mikhail Lichinitser, Miguel Ángel Climent, Eva Ciruelos, B. Ojeda, Mauro Mansutti, А. А. Божок, Roberta Baronio, A. Feyereislova, Claire Barton, Pinuccia Valagussa, José Baselga - The Lancet 2010 cited by 1,268

  4. Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study

    Authors: Leonard B. Saltz, Stephen Clarke, Eduardo Díaz‐Rubio, Werner Scheithauer, Arié Figer, Ralph Wong, Sheryl Koski, Mikhail Lichinitser, Tsai‐Shen Yang, Fernando Rivera, Félix Couture, Florin Sirzén, Jim Cassidy - Journal of Clinical Oncology 2008 cited by 2,963

  5. Denosumab Compared With Zoledronic Acid for the Treatment of Bone Metastases in Patients With Advanced Breast Cancer: A Randomized, Double-Blind Study

    Authors: Alison Stopeck, Allan Lipton, Jean-Jacques Body, Guenther G. Steger, Katia Tonkin, Richard H. De Boer, Mikhail Lichinitser, Yasuhiro Fujiwara, Denise A. Yardley, María Eugenia Ibarrarán Viniegra, Michelle Fan, Qi Jiang, Roger Dansey, Susie Jun, Ada Braun - Journal of Clinical Oncology 2010 cited by 1,593

  6. Lapatinib Combined With Letrozole Versus Letrozole and Placebo As First-Line Therapy for Postmenopausal Hormone Receptor–Positive Metastatic Breast Cancer

    Authors: Stephen Johnston, John Pippen, Xavier Pivot, Mikhail Lichinitser, Saeed Sadeghi, Véronique Dièras, Henry Gómez, Gilles Romieu, Alexey Manikhas, M. John Kennedy, Michael F. Press, J. Maltzman, Allison Florance, Lisa O’Rourke, Cristina Oliva, Steven Stein, Mark D. Pegram - Journal of Clinical Oncology 2009 cited by 1,024

  7. Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort

    Authors: Luca Gianni, W. Eiermann, Semiglazov Vf, Aňa Lluch, Sergei Tjulandin, Milvia Zambetti, Angela Moliterni, Federico Vázquez, M. Byakhov, Mikhail Lichinitser, Miguel Ángel Climent, Eva Ciruelos, B. Ojeda, Mauro Mansutti, А. А. Божок, Domenico Magazzù, Dominik Heinzmann, Jutta Steinseifer, Pinuccia Valagussa, José Baselga - The Lancet Oncology 2014 cited by 491

  8. Results of the CONFIRM Phase III Trial Comparing Fulvestrant 250 mg With Fulvestrant 500 mg in Postmenopausal Women With Estrogen Receptor–Positive Advanced Breast Cancer

    Authors: Angelo Di Leo, Guy Jérusalem, Luboš Petruželka, Roberto Torres, Igor Bondarenko, Р. Ш. Хасанов, Didier Verhoeven, José Luiz Pedrini, И А Смирнова, Mikhail Lichinitser, Kelly Pendergrass, Sally Garnett, Justin P.O. Lindemann, Francisco Sapunar, Miguel Martín - Journal of Clinical Oncology 2010 cited by 633

  9. Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial

    Authors: Jean‐Jacques Grob, Mayur M. Amonkar, Bogusława Karaszewska, Jacob Schachter, Reinhard Dummer, Andrzej Maćkiewicz, Daniil Stroyakovskiy, Kamil Drucis, Florent Grange, Vanna Chiarion‐Sileni, Piotr Rutkowski, Mikhail Lichinitser, E. Levchenko, Pascal Wolter, Axel Hauschild, Georgina V. Long, Paul Nathan, Antoni Ribas, Keith T. Flaherty, Peng Sun, Jeffrey J. Legos, Diane Opatt McDowell, Bijoyesh Mookerjee, Dirk Schadendorf, Caroline Robert - The Lancet Oncology 2015 cited by 262

  10. Randomized Phase II, Double-Blind, Placebo-Controlled Study of Exemestane With or Without Entinostat in Postmenopausal Women With Locally Recurrent or Metastatic Estrogen Receptor-Positive Breast Cancer Progressing on Treatment With a Nonsteroidal Aromatase Inhibitor

    Authors: Denise A. Yardley, Roohi Ismail‐Khan, Bohuslav Melichar, Mikhail Lichinitser, Pamela N. Münster, Pamela Klein, Scott Cruickshank, Kathy D. Miller, Min J. Lee, Jane B. Trepel - Journal of Clinical Oncology 2013 cited by 418

  11. Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial

    Authors: Yoon‐Koo Kang, Won Ki Kang, D.B. Shin, Jingyu Chen, Jianping Xiong, Jie Wang, Mikhail Lichinitser, Z. Guan, Р. Ш. Хасанов, Leizhen Zheng, Manuel Jesus Philco-Salas, T. Suarez, Javier Gutiérrez Santamarı́a, Gerhard Förster, P. McCloud - Annals of Oncology 2009 cited by 777

  12. Randomized Phase III Study of Capecitabine Plus Oxaliplatin Compared With Fluorouracil/Folinic Acid Plus Oxaliplatin As First-Line Therapy for Metastatic Colorectal Cancer

    Authors: Jim Cassidy, Stephen Clarke, Eduardo Díaz‐Rubio, Werner Scheithauer, Arié Figer, Ralph Wong, Sheryl Koski, Mikhail Lichinitser, Tsai‐Shen Yang, Fernando Rivera, Félix Couture, Florin Sirzén, Leonard B. Saltz - Journal of Clinical Oncology 2008 cited by 864

  13. Final Overall Survival: Fulvestrant 500 mg vs 250 mg in the Randomized CONFIRM Trial

    Authors: Angelo Di Leo, Guy Jérusalem, Luboš Petruželka, Roberto Torres, Igor Bondarenko, Р. Ш. Хасанов, Didier Verhoeven, José Luiz Pedrini, И А Смирнова, Mikhail Lichinitser, Kelly Pendergrass, Luca Malorni, Sally Garnett, Yuri Rukazenkov, Miguel Martín - JNCI Journal of the National Cancer Institute 2013 cited by 328

  14. CNS relapses in patients with HER2-positive early breast cancer who have and have not received adjuvant trastuzumab: a retrospective substudy of the HERA trial (BIG 1-01)

    Authors: Bernhard C. Pestalozzi, Eileen Holmes, Evandro de Azambuja, Otto Metzger, Laurence Hogge, Matt Scullion, István Láng, Andrew Wardley, Mikhail Lichinitser, Roberto Sánchez, Volkmar Müller, David Dodwell, Richard D. Gelber, Martine Piccart, David Cameron - The Lancet Oncology 2013 cited by 211

  15. Patients' preferences for subcutaneous trastuzumab versus conventional intravenous infusion for the adjuvant treatment of HER2-positive early breast cancer: final analysis of 488 patients in the international, randomized, two-cohort PrefHer study

    Authors: Xavier Pivot, Joseph Gligorov, Volkmar Müller, Giuseppe Curigliano, Ann Knoop, Sunil Verma, Valerie Jenkins, Nana Scotto, Stuart Osborne, Lesley Fallowfield, Lesley Fallowfield, Valerie Jenkins, Justine Kilkerr, C. Langridge, Kathryn Monson, Erik Jakobsen, Mette Holck Nielsen, Soeren Linnet, Ann Knoop, Xavier Pivot, Hervé Bonnefoi, Mireille Mousseau, Laurent Zelek, Hugues Bourgeois, Claudia Lefeuvre, Thomas Bachelot, Thierry Petit, Étienne Brain, Christelle Lévy, Joseph Gligorov, Doris Augustin, Heiko Graf, Georg Heinrich, Hendrik Kroening, Sherko Küemmel, Volkmar Müller, Friedrich Overkamp, Tjoung‐Won Park‐Simon, Marcus Schmidt, Lidia Perlova-Griff, Christopher Wolf, Marco Colleoni, Alberto Ballestrero, Antônio Bernardo, Angela Stefania Ribecco, Luca Gianni, Giuseppe Curigliano, E. Brewczynska, Jacek Jassem, Vadim Shirinkin, Alexey Manikhas, В. В. Дворниченко, Mikhail Lichinitser, Semiglazov Vf, Guzel Mukhametshina, Irina Bulavina, Enrique Espinosa Arranz, Francisco Carabantes Ocón, Guillermo López-Vivanco, Javier Salvador Bofill, Ignacio Porras Quintela, Alfonso Sánchez Muñoz, Yolanda Fernández Pérez, Javier Cassinello Espinosa, Jose Alvarez, Rodrigo Lastra del Prado, LuisLa Cruz De Merino, José Manuel Pérez García, Santos Enrech Francés, Per Edlund, Bengt Norberg, Anna-Karin Wennstig, Pehr Lind, Nik Hauser, Christoph Tausch, Celalettin Camcı, Fikret Arpacı, Hüseyin Abalı, Rüçhan Uslu, Saad Tahir, Duncan Wheatley, Stephen Chan, Peter Barrett‐Lee, Karen McAdam, Richard Simcock, Russell Burcombe, Robert H. El-Maraghi, Nadia Califaretti, Silvana Spadafora, Sandeep Sehdev, Amer Sami, Sunil Verma - Annals of Oncology 2014 cited by 176

  16. An attempt to prevent senescence: A mitochondrial approach

    Authors: Vladimir P. Skulachev, Vladimir N. Anisimov, Yuri N. Antonenko, Lora E. Bakeeva, Boris V. Chernyak, В. П. Еричев, О. Ф. Филенко, Natalya I. Kalinina, Valery I. Kapelko, Natalya G. Kolosova, Kopnin Bp, Galina A. Korshunova, Mikhail Lichinitser, Л. А. Обухова, E. G. Pasyukova, О. И. Писаренко, Vitaly A. Roginsky, E. K. Ruuge, Ivan I. Senin, Inna I. Severina, Maxim V. Skulachev, Spivak Im, Vadim N. Tashlitsky, Tkachuk Va, M. Yu. Vyssokikh, L. S. Yaguzhinsky, Dmitry B. Zorov - Biochimica et Biophysica Acta (BBA) - Bioenergetics 2008 cited by 426

  17. Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I–III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial

    Authors: Gustavo Ismael, Roberto Hegg, Susanne Muehlbauer, Dominik Heinzmann, Bert Lum, Sung‐Bae Kim, Tadeusz Pieńkowski, Mikhail Lichinitser, Semiglazov Vf, Bohuslav Melichar, Christian Jackisch - The Lancet Oncology 2012 cited by 346

  18. Prognostic and predictive value of AJCC-8 staging in the phase III EORTC1325/KEYNOTE-054 trial of pembrolizumab vs placebo in resected high-risk stage III melanoma

    Authors: Alexander M.M. Eggermont, Christian U. Blank, Mario Mandalà, Georgina V. Long, Victoria Atkinson, Stéphane Dalle, Andrew Haydon, Mikhail Lichinitser, Adnan Khattak, Matteo S. Carlino, Shahneen Sandhu, James Larkin, Susana Puig, Paolo A. Ascierto, Piotr Rutkowski, Dirk Schadendorf, Rutger H.T. Koornstra, Leonel F. Hernandez‐Aya, Anna Maria Di Giacomo, Alfonsus JM. van den Eertwegh, Jean-Jacques Grob, Ralf Gutzmer, Rahima Jamal, Paul Lorigan, Robert Lupinacci, Clemens Krepler, Nageatte Ibrahim, Michal Kiciński, Sandrine Marréaud, Alexander C. J. van Akkooi, Stefan Suciu, Caroline Robert - European Journal of Cancer 2019 cited by 86

  19. Multicenter Phase III Comparison of Cisplatin/S-1 With Cisplatin/Infusional Fluorouracil in Advanced Gastric or Gastroesophageal Adenocarcinoma Study: The FLAGS Trial

    Authors: Jaffer A. Ajani, W. Rodriguez, G. Bodoky, Vladimir Moiseyenko, Mikhail Lichinitser, В. А. Горбунова, Ihor Vynnychenko, August Garin, István Láng, S. Falcon - Journal of Clinical Oncology 2010 cited by 565

  20. A randomised, double-blind, placebo-controlled phase 2 study of trebananib (AMG 386) in combination with FOLFIRI in patients with previously treated metastatic colorectal carcinoma

    Authors: Marc Peeters, A. H. Strickland, Mikhail Lichinitser, Amritha Suresh, G. Manikhas, Jeremy Shapiro, Wojciech Rogowski, Xin‐En Huang, Benjamin Wu, Douglas Warner, Rajul K. Jain, Niall C. Tebbutt - British Journal of Cancer 2013 cited by 79

  21. HannaH phase III randomised study: Association of total pathological complete response with event-free survival in HER2-positive early breast cancer treated with neoadjuvant–adjuvant trastuzumab after 2 years of treatment-free follow-up

    Authors: Christian Jackisch, Roberto Hegg, Daniil Stroyakovskiy, Jin‐Seok Ahn, Bohuslav Melichar, Shin‐Cheh Chen, Sung‐Bae Kim, Mikhail Lichinitser, Elżbieta Starosławska, Georg Kunz, S. Falcon, Shou‐Tung Chen, A. Crepelle-Fléchais, Dominik Heinzmann, Mona Shing, Xavier Pivot - European Journal of Cancer 2016 cited by 78

  22. First-Line Treatment of Advanced Breast Cancer With Sunitinib in Combination With Docetaxel Versus Docetaxel Alone: Results of a Prospective, Randomized Phase III Study

    Authors: Jonas Bergh, Igor M. Bondarenko, Mikhail Lichinitser, Annelie Liljegren, Richard Greil, Nataliya L. Voytko, А. Н. Махсон, Javier Cortés, Alain Lortholary, Joachim Bischoff, Arlene Chan, Suzette Delaloge, Xin Huang, Kenneth A. Kern, C. Giorgetti - Journal of Clinical Oncology 2012 cited by 262

  23. Comparison of Fulvestrant Versus Tamoxifen for the Treatment of Advanced Breast Cancer in Postmenopausal Women Previously Untreated With Endocrine Therapy: A Multinational, Double-Blind, Randomized Trial

    Authors: Anthony Howell, J.F.R. Robertson, P. Abram, Mikhail Lichinitser, Richard Elledge, Emilio Bajetta, Toru Watanabe, Charles Morris, Alan Webster, Isaiah W. Dimery, C. Kent Osborne - Journal of Clinical Oncology 2004 cited by 425

  24. Randomized Phase III Study of High-Dose Fluorouracil Given As a Weekly 24-Hour Infusion With or Without Leucovorin Versus Bolus Fluorouracil Plus Leucovorin in Advanced Colorectal Cancer: European Organization of Research and Treatment of Cancer Gastrointestinal Group Study 40952

    Authors: C-H Köhne, J. Wils, M. Lorenz, Patrick Schöffski, R. Voigtmann, Carsten Bokemeyer, Manfred P. Lutz, Ulrich R. Kleeberg, Karsten Ridwelski, R. Souchon, M. Elserafi, U. Weiss, Oswald Burkhard, H. Rückle, Mikhail Lichinitser, T. Langenbuch, Werner Scheithauer, B. Barón, M.L. Couvreur, Hans‐Joachim Schmoll - Journal of Clinical Oncology 2003 cited by 160